3-(4-{[4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]m ethyl}phenyl)-2-phenyl-6-quinoxalinecarboxylic acid
更新时间：2024-03-06 22:10:18
![3-(4-{[4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]m ethyl}phenyl)-2-phenyl-6-quinoxalinecarboxylic acid结构式](https://image.chemsrc.com/caspic/470/612847-29-7.png)
3-(4-{[4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]m ethyl}phenyl)-2-phenyl-6-quinoxalinecarboxylic acid结构式
|
常用名 | 3-(4-{[4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]m ethyl}phenyl)-2-phenyl-6-quinoxalinecarboxylic acid | 英文名 | 3-(4-{[4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]m ethyl}phenyl)-2-phenyl-6-quinoxalinecarboxylic acid |
|---|---|---|---|---|
| CAS号 | 612847-29-7 | 分子量 | 555.626 | |
| 密度 | 1.3±0.1 g/cm3 | 沸点 | N/A | |
| 分子式 | C34H29N5O3 | 熔点 | N/A | |
| MSDS | N/A | 闪点 | N/A |
| 英文名 | 3-(4-{[4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]m ethyl}phenyl)-2-phenyl-6-quinoxalinecarboxylic acid |
|---|---|
| 英文别名 | 更多 |
| 密度 | 1.3±0.1 g/cm3 |
|---|---|
| 分子式 | C34H29N5O3 |
| 分子量 | 555.626 |
| 精确质量 | 555.227051 |
| PSA | 104.37000 |
| LogP | 5.66 |
| 折射率 | 1.698 |
|
~%
3-(4-{[4-(2-Oxo... 612847-29-7 |
| 文献：Lindsley, Craig W.; Zhao, Zhijian; Leister, William H.; Robinson, Ronald G.; Barnett, Stanley F.; Defeo-Jones, Deborah; Jones, Raymond E.; Hartman, George D.; Huff, Joel R.; Huber, Hans E.; Duggan, Mark E. Bioorganic and Medicinal Chemistry Letters, 2005 , vol. 15, # 3 p. 761 - 764 |
|
~%
3-(4-{[4-(2-Oxo... 612847-29-7 |
| 文献：Lindsley, Craig W.; Zhao, Zhijian; Leister, William H.; Robinson, Ronald G.; Barnett, Stanley F.; Defeo-Jones, Deborah; Jones, Raymond E.; Hartman, George D.; Huff, Joel R.; Huber, Hans E.; Duggan, Mark E. Bioorganic and Medicinal Chemistry Letters, 2005 , vol. 15, # 3 p. 761 - 764 |
|
~%
3-(4-{[4-(2-Oxo... 612847-29-7 |
| 文献：Lindsley, Craig W.; Zhao, Zhijian; Leister, William H.; Robinson, Ronald G.; Barnett, Stanley F.; Defeo-Jones, Deborah; Jones, Raymond E.; Hartman, George D.; Huff, Joel R.; Huber, Hans E.; Duggan, Mark E. Bioorganic and Medicinal Chemistry Letters, 2005 , vol. 15, # 3 p. 761 - 764 |
![1-(4-((4-(2-OXO-2,3-DIHYDRO-1H-BENZO[D]IMIDAZOL-1-YL)PIPERIDIN-1-YL)METHYL)PHENYL)-2-PHENYLETHANE-1,2-DIONE结构式](https://image.chemsrc.com/caspic/269/612848-74-5.png)
![2-(4-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]methyl}phenyl)-3-phenylquinoxaline-6-carboxylic acid结构式](https://image.chemsrc.com/caspic/067/612847-31-1.png)
![1,2-乙烷二酮,1-[4-(溴甲基)苯基]-2-苯基结构式](https://image.chemsrc.com/caspic/133/18189-19-0.png)
| 3-(4-{[4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]methyl}phenyl)-2-phenyl-6-quinoxalinecarboxylic acid |
| 3-(4-{[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]methyl}phenyl)-2-phenylquinoxaline-6-carboxylic acid |
| 3-(4-{[2-(2-methyl-1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-(2E)-2-propenoic acid methyl ester |
| (E)-Methyl 3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)acrylate |
| 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- |
